Cancer Policy Monitor: May 8, 2018      

May Is National Cancer Research Month      

May is National Cancer Research Month, during which the American Association for Cancer Research partners with advocacy groups, cancer centers, and research institutions to raise awareness of the high-quality, innovative cancer research happening across the country and around the world. Throughout the month, you can help support a global awareness campaign about the importance of cancer research. This year’s theme is “Cancer Research Saves Lives.”

Share a cancer research story

Are you a cancer researcher or a patient, advocate, or community member who has benefited from cancer research? Share your story for National Cancer Research Month. You can post it on your personal blog or social media pages using the hashtag #ResearchSavesLives and #NCRM18.

Engage on social media

Like the National Cancer Research Month page on Facebook and make sure to check out tweets and posts tagged with #ResearchSavesLives and #NCRM18. Engage with advocates who are sharing their stories, start conversations, ask questions, and share your own story with them.

You can also download the Cancer Research Saves Lives graphics and use them on your blog, website, and social media posts.

Become an advocate

Talk to your elected officials about the importance of cancer research, the need for continued funding and the latest lifesaving breakthroughs. In the United States, you can do so by sending them a letter. In addition, please encourage your social and digital followers and fans to do the same at

Top of page

Advocates from AACR and AACI Spend a Day on Capitol Hill      

On April 24, representatives of the AACR and the Association of American Cancer Institutes (AACI) visited federal legislators to express their gratitude for a bipartisan spending package for fiscal year 2018 that prioritized funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA).

In March, Congress delivered a $3 billion increase for the NIH, raising its budget 8.3 percent to $37 billion. As part of the package, the NCI received $5.9 billion, which included $300 million in funding for the Beau Biden Cancer Moonshot Initiative, one of the key initiatives of the 21st Century Cures Act. Additionally, an initial investment of $15 million was provided for the FDA’s Oncology Center of Excellence.

“We can’t thank our nation’s policymakers enough for their extraordinary and sustained commitments to the NIH and the FDA,” said Elizabeth M. Jaffee, MD, president of the AACR, and deputy director for the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins and associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy. “It’s very clear that our nation’s leaders recognize that we are in an era of unprecedented research opportunities, which will result in major progress against cancer and the numerous other diseases that afflict so many Americans.”

Joined by members who are cancer researchers, physicians, survivors, patient advocates, and cancer center directors, the AACR and AACI also asked Congress to provide at least $39.3 billion for the NIH in fiscal year 2019, and $20 million for the FDA Oncology Center of Excellence.

Before visiting legislators, Hill Day participants gathered for a breakfast briefing from U.S. Rep. Tom Cole (R-Oklahoma), who serves as the chairman of the House Appropriations Subcommittee on Labor, HHS, Education, and Related Agencies, the subcommittee that oversees NIH funding.

Chairman Cole said that he and his counterpart Sen. Roy Blunt (R-Missouri), agreed when they became chairmen of the Labor, HHS, Education Appropriations Subcommittees in the House and Senate, respectively, that they would strive to increase the NIH’s budget each year by the rate of biomedical inflation, along with a healthy percentage of real growth, in order to ensure robust, sustained, and predictable funding increases for the agency. Their steadfast efforts have resulted in the NIH budget growing by 23 percent over the past three years.

“That additional support was incredibly welcome news and is vital for continued success for cancer research and the delivery of care,” said AACI Executive Director Barbara Duffy Stewart, MPH. “We need to maintain this momentum.” Mary Gillam, a cancer survivor and patient advocate who recently received treatment at the UNC Lineberger Comprehensive Cancer Center for pancreatic cancer, also addressed attendees.

All told, 74 cancer research advocates from 21 states and the District of Columbia participated in 125 meetings with lawmakers and staff. Thirty-two cancer centers were represented.

AACR and AACI are two of the largest organizations in the field, representing more than 40,000 laboratory researchers, physician-scientists, other health care professionals, and patient advocates, and 98 cancer centers across the country and overseas. For the past 11 years, the groups have shared their perspectives on Capitol Hill, underscoring how cancer research is saving lives and transforming patient care.

Top of page

AACR Scientist↔Survivor Program Celebrates 20 Years     

The AACR Scientist↔Survivor Program, a unique program designed to build bridges and unity among the leaders of the scientific and cancer survivor and patient advocacy communities worldwide, is celebrating its 20th year this year. You can watch a special AACR Scientist↔Survivor Program 20th anniversary video here.

The program provides an opportunity for patient advocates to learn about cancer research and to interact with scientists, doctors, health professionals, and other advocates. These groups come together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research in cancer health disparities.

Anna D. Barker, PhD, who has been chairperson of the AACR Scientist↔Survivor Program since she conceptualized the program more than two decades ago, received the 2018 AACR Distinguished Award for Exceptional Leadership in Cancer Science Policy and Advocacy.

Dr. Barker is the director of the National Biomarker Development Alliance; the director of Transformative Healthcare Knowledge Networks; co-director, Complex Adaptive Systems; and a professor in the School of Life Sciences at Arizona State University.

Aside from being chairperson of the AACR Scientist↔Survivor Program, she has also provided outstanding leadership in cancer science policy and advocacy for the AACR through her work as chair of the AACR’s Public Education Committee (now the Science Policy and Government Affairs Committee) from 1993-2002. She continues to serve on this committee, lending her considerable expertise to its initiatives. In addition, she served on the AACR board of directors from 1995-1996 and 1998-2001. She was deputy director of the National Cancer Institute from 2002-2010.

“Dr. Barker’s innovative leadership in cancer advocacy has driven the success of her brainchild, the AACR Scientist↔Survivor Program, for it brings together cancer scientists and physicians along with cancer advocates at our scientifically vibrant Annual Meeting and at the Science of Cancer Health Disparities Meeting,” said AACR Chief Executive Officer Margaret Foti, PhD, MD (hc). “This unique program has had an indelible, positive effect on the professional and personal lives of both cancer researchers and advocates, and it has been hailed around the world as the most important initiative of its type.”

Top of page

Capitol Corner: AACR Interviews Members of Congress      

Every month, the AACR will be interviewing several members of Congress from both sides of the aisle to get their personal story and views on cancer research. This month, we interviewed Senator Jon Tester (D-Montana) and Representative Dave Reichert (R-Washington).

Read our previous interviews with Senator Gary Peters (D-Michigan), Representative Charlie Crist (D-Florida), Senator Susan Collins (R-Maine), Representative Dwight Evans (D-Pennsylvania), Senator Chuck Grassley (R-Iowa), Senator Tammy Baldwin (D-Wisconsin), Representative Brett Guthrie (R-KY) and Representative Suzan DelBene (D-WA)

Senator Jon Tester (D-Montana)  

Can you share with our readers, many of whom are cancer patients, advocates, and researchers, your personal connection to cancer?

I, like so many other Americans, have known far too many people who have had cancer. When I was nine years old I lost three of my fingers in a meat grinder accident. My father took me to the hospital and ran into a friend of his while we were there. My father was upset because his son had lost his fingers. When he asked why his friend was there, his friend said his son, who was my age, had leukemia. That boy died about three months after I got out of the hospital. That kind of stuff sticks with you when you’re a kid.

How has the experience of dealing with cancer in your community, both personally and from stories you’ve heard from your constituents, shape your views as a policymaker and a public official?

My family has also dealt with cancer. About three years ago my son-in-law got in a car-wreck while my grandson was in the car. He was passing a truck with a bunch of ladders on it and one flew off the back and when he swerved to miss it he ended up on the other side of the freeway after taking a few rolls. Neither of them were hurt besides a few bumps and bruises, but he decided to go get checked out because he had insurance and could afford to do so.

During that trip to the doctor he found out that he had early stage thyroid cancer. They got it really early, but only because of that car accident and only because he could afford to go get an MRI. He’s cancer-free because of that insurance and because of how far medical innovation has come. That’s why I believe passionately about access to health care. It saves lives and can help quality of life.

As a member of the Senate Appropriations Committee, you have supported of efforts to provide the National Institutes of Health (NIH) with the largest increases in funding in more than a decade. Why do you believe that robust funding increases for NIH are so important at this time? What would you say to your colleagues in the legislative branch who may not understand as you do how important federal investment in medical research is to our nation?

American research and innovation is what makes our nation a global leader. Public funding is important, now more than ever, to ensure that we see good, lifesaving research. Without federal investment, research groups might be forced to rely on corporations who have outside interests beyond America’s health, or shut down their research altogether.

How can groups like the AACR and patient advocates best communicate the importance of medical research to the members of Congress? 

It is incredibly important that members of Congress hear from people in their home states about how important these investments are. Send emails and make calls, tell your stories about how cancer has impacted you, and let your lawmakers know you’re watching.

Do you think we have made progress in terms of raising awareness of the importance of NIH funding to saving lives and helping the American economy?

Providing federal funding for medical research can not only save lives, it will save taxpayer dollars in the long run. Either we pay for funding now or we pay for increased health care costs down the road. As a member of the Senate Appropriations Committee, I have pushed for responsible investments and fought against budget cuts for the National Institutes of Health. The fact that we’ve made these investments shows that there are a lot of folks in Congress who recognize how important NIH funding is.

Can you tell us more about other efforts—legislation and otherwise—that you have worked on or are currently working on in support of better prevention, detection and treatment of cancer?

In the current session of Congress I have sponsored multiple bills in hopes of supporting better prevention, detection and treatment of cancer.  I am supporting the Firefighter Cancer Registry Act to develop a voluntary registry to collect data on cancer incidence among fire fighters so we can better protect those folks on the front lines.

I am also sponsoring the Removing Barriers to Colorectal Cancer Screening Act to waive coinsurance under Medicare for colorectal cancer screening tests, regardless of whether therapeutic intervention is required during the screening. In addition, I urged the chairman and ranking members of the Senate Appropriations Committee and the Appropriations Subcommittee on Health and Human Services to maintain a strong commitment to funding for the NIH.

Do you have anything you would like to say to the AACR and our scientists and physicians who have dedicated their careers to making progress against cancer?

Thank you for all the work you do. Too many Americans are affected by cancer and the work you do makes me hopeful that one day we’ll find a cure.

Is there anything we didn’t discuss that you would like to add?

Cancer can happen at any time to anyone, regardless of age, wealth, or race. Medical research can save countless lives if properly funded.

Top of page

Representative Dave Reichert (R-Washington) 

Can you share with our readers, many of whom are cancer patients, advocates, and researchers, your personal connection to cancer?

There are three people from my life that have experienced cancer – my mother, my brother, and my godson. What I have learned from all three experiences is that our doctors, nurses, patients and their families give their all to fight this disease, and watching a loved one suffer never gets any easier. That is why I wholeheartedly believe we must do all we can to support medical research and the discovery of new treatments and cures so that we can better arm doctors and patients in their fight against cancer.

Several years ago, my mother lost her 18-month battle with pancreatic cancer. While she fought incredibly hard, I saw firsthand during her battle that there was still so much we needed to learn. This year pancreatic cancer surpassed breast cancer to become the third leading cause of deaths from cancer. The pancreatic cancer survival rate is just nine percent, and most patients die within a year of their diagnosis. This is a truly devastating diagnosis for patients and their families.  

Thanks to an expert team of doctors and advanced research, my brother's prostate cancer was found early and he was able to fight it and beat it. He beat the odds with a type of cancer that is a death sentence for too many. Without such an early diagnosis, he would not be living the full and healthy life he is today.

My godson, Kyle, was diagnosed with brain cancer when he was just 18 months old. With the help of a great team of doctors, he was able to fight the cancer, but his life was completely changed because of it. Today, he is confined to a wheelchair and requires around the clock care at home. I am truly grateful for the commitment of Kyle's doctors, nurses, and caregivers to his health and well-being. Because of their efforts, we get to cherish this young, joyful boy and his smile that can light up the room. He instantly melts the heart of anyone he meets. 

Over the past few decades, we have beat impossible odds and discovered new ways to fight cancer, but there is still more we need to study, including prevention, early detection, and treatments that not only attack the cancer but also improve the quality of life for the patient.  

How has the experience of dealing with cancer in your community, both personally and from stories you've heard from your constituents, shape your views as a policymaker and a public official?

Each of these loved ones of mine faced a different diagnosis, at a different age, and at a different time. But what they all had in common, was they were fighting a disease that is destructive and changed their lives in one way or another. For Kyle and my brother, they face lasting, long-term effects from their illnesses.

As I've seen from my personal family experiences and those my constituents have shared with me, cancer can have a lasting impact that affects an individual's ability to work, spend time with their families, and lead a normal life. For those who cannot work, they are left to the disability system and what type of insurance they can afford which dictates their access to the best physicians and care they need. And this is not to mention on top of the exorbitant costs they often face to maintain their care.

I've also learned that cancer creates a community – and if there ever was a silver lining in such a horrible disease I think that is it. Cancer not only touches the patient, but also their family, friends, and loved ones. It's an emotional battle and takes a toll on everyone, but also brings us closer together. I am inspired by the stories I've heard of patients helping patients, and families creating networks and support groups for one another. It's also the little things like a friend volunteering to watch the dog or house sit so the family can be together at the hospital, or the neighbor bringing over freezer meals so when facing the unimaginable, the patient and family can focus on what matters most – each other and getting healthy.

You're a founding member of the Congressional Caucus on the Deadliest Cancers, and have supported NIH funding increases and the 21st Century Cures Act. Why do you believe that NIH funding is so important? What would you say to your colleagues in the legislative branch who may not understand as you do how important federal investment in medical research is to our nation?

I am a strong supporter of medical research because I have seen how it can save lives. In my brother's case, he was able to beat a type of cancer that kills most people who get it thanks to an early diagnosis and quick treatment. Without the long hours you and your colleagues have dedicated to finding cures and treatments, our success rate would not be what it is today.

But in many cases you cannot do this work without federal resources, which is why I have been such a committed advocate for robust funding for research. It is essential that my colleagues and I continue to fund research programs at the NIH, colleges and universities, and other research centers. As I have experienced, this work saves lives. Throughout my career in Congress, I have had the opportunity to meet with doctors and scientists from around Washington state who have devoted their lives to finding new treatments. They have showed me some of their innovative research such as using stem cells or reprograming DNA – leading to more information about cancer and possible cures.

Most importantly, I support this work because without it, people don't have hope. I helped form the Congressional Caucus on the Deadliest Cancers in part because of my experience watching my mother lose her battle to pancreatic cancer. It's a platform for me to help educate other members on the importance of medical research, and especially for recalcitrant cancers like pancreatic cancer. If we do nothing, what hope do patients and families like mine have when given such a devastating diagnosis? Investing in medical research is our best hope for one day finding a cure, and that hope is what gets patients and families through some of the toughest times during their battle with cancer.

How can groups like the AACR and patient advocates best communicate the importance of medical research to the members of Congress? Do you think we have made progress in terms of raising awareness of the importance of NIH funding to saving lives and helping the American economy?

It is extremely important that you continue to engage with your representatives in Congress and their staff on this subject. Hearing your stories and learning about your work firsthand is invaluable because you are the true experts. It is also important to not only share the work that is in the pipeline, but also examples of success stories from past investments and how that research is transforming lives today.

Since I was first elected, there has been great progress in making this issue a priority in Congress resulting in tremendous strides in funding for medical research. The Bipartisan Budget Act of 2018 and the Fiscal Year 2018 Omnibus Appropriations Act are proof that your message is getting through and your advocacy is having a positive impact. Both of these bills passed with bipartisan support and both increased funding for the NIH. During a time when partisan politics can capture the national headlines, support for NIH research continues to be an area of bipartisan agreement.

Can you tell us more about other efforts—legislation and otherwise—that you have worked on or are currently working on in support of better prevention, detection ,and treatment of cancer?

In March we celebrated Lymphedema Awareness Month. One of my top priorities in my final year in Congress is to help the millions of seniors living with lymphedema access the compression garments they need to effectively treat and manage their disease. I am the proud sponsor of legislation to do just that, the Lymphedema Treatment Act (H.R. 930), which has the support of over 380 members of Congress from both chambers and both sides of aisle. This bipartisan, bicameral piece of legislation would provide Medicare coverage of compression garments for those suffering from lymphedema. While there are primary forms of lymphedema, the majority are secondary cases with the overwhelming amount being cancer-related. After fighting a cancer diagnosis, it's heartbreaking that patients can be left with this debilitating disease that has no cure. Fortunately, treatment exists and it's my mission to ensure Medicare covers the treatment items patients need. I am leading this legislative effort, but at a hearing before the House Committee on Ways and Means I also received a commitment from Health and Human Services Secretary Alex Azar that he will work with Congress to ensure we get lymphedema patients the compression items they need.

Additionally, this Congress I have cosponsored several pieces of legislation that support cancer patients. The Palliative Care and Hospice Education and Training Act (H.R. 1676), by Representative Engle (D-NY), seeks to improve federally supported research in palliative care, train more non-physician providers in palliative care, and create a national palliative care public education and awareness campaign.

I am also a cosponsor of the Removing Barriers to Colorectal Cancer Screening Act of 2017 (H.R. 1017), introduced by Representative Charlie Dent (R-PA). This bill fixes an issue in Medicare so that patients are covered without cost-sharing if a polyp is found and removed during a routine colonoscopy procedure, treating it as a screening rather than a diagnostic procedure.

Lastly, I am a cosponsor of the Childhood Cancer STAR Act (H.R. 820), which was reintroduced this Congress by Representative Michael McCaul (R-TX) after passing the House last Congress. This important bill provides a comprehensive plan to advance pediatric cancer research and child-focused cancer treatments, while also improving childhood cancer surveillance and offering enhanced resources for survivors and those impacted by kids' cancers.

Do you have anything you would like to say to the AACR and our scientists and physicians who have dedicated their careers to making progress against cancer?

Words cannot fully express how truly grateful I am for your hard work and dedication to finding cures for this dreadful disease. Thank you for everything you have done and the work you will continue doing. You have already saved so many people's lives and positively touched families like mine. What you all do every day is helping to cure people and prolong the lives of children, teens, and adults around the world. You are giving people hope and a second chance at life, which is the greatest gift you could ever give to someone.

Every day you go to work could bring an answer or a breakthrough and save someone's life. Do not give up hope. You are the hope people all over the world are relying on for cures and a chance at life. Always know you have the support of Congress and the American people, and we have every confidence in you and what you do each and every day.

I pray for you each day that God will guide your hearts, minds, and the talents with which you have been blessed. You have a unique calling and we are so thankful for everything you are doing in this field. Thank you!

Top of page

AACR’s 110th Anniversary Resolution Introduced in Congress     

The American Association for Cancer Research (AACR) expresses its appreciation to U.S. Rep. Bob Brady (D-Pennsylvania) for his introduction of a House resolution recognizing the 110th anniversary of the AACR. The resolution, H.Res. 819, is co-sponsored by Reps. Patrick Meehan and Ryan Costello, both Republicans from Pennsylvania.

“We are honored that Congressman Brady, along with Congressmen Meehan and Costello, have introduced this special resolution to mark an extraordinary milestone for the AACR,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “Since its founding in 1907, the AACR and its members have been at the forefront of every major breakthrough against cancer, and you can be sure that the AACR will continue to push forward a bold vision to defeat cancer by dramatically reducing incidence and deaths while improving the quality of life for all.”

The AACR was founded on May 7, 1907, by a group of 11 distinguished scientists and physicians and held its first scientific meeting Nov. 15, 1907. Today, the AACR has a membership of over 40,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates in 120 countries. The AACR’s members have included 62 Nobel Laureates.

“The diagnosis of cancer was once a death sentence, but because of the work of the AACR, hundreds of thousands of patients today are cancer survivors,” said Brady. “I am pleased to recognize the 110th anniversary of the AACR, the world’s first and largest professional organization dedicated to the conquest of cancer. So, as we look back on the AACR’s lifesaving history, we can also look ahead to the continued scientific progress in the fight against cancer and the training of the next generation of cancer researchers led by the AACR.”

The resolution led by the three Philadelphia-area members of Congress is part of a yearlong celebration marking the anniversary. The Annual Meeting 2017 featured a special display and publication titled “Landmarks in Cancer Research,” and last November the AACR hosted an event in Washington, D.C., to honor its achievements in cancer research over the last 110 years. The congressional resolution was featured at the Annual Meeting 2018 in Chicago.

Top of page

Webcasts of AACR Annual Meeting 2018 Policy Sessions      

Beginning May 9, webcasts of Regulatory Science and Policy track and Science Policy track sessions at the AACR Annual Meeting 2018 will be available free of charge. The webcast of NCI Director Norman E. Sharpless’ address and fireside chat is already available. Links to each session's webcast can be found below.

NCI Director's Address and Fireside Chat with AACR Leaders

Watch the webcast.

Norman E. Sharpless - National Cancer Institute, Bethesda, MD
Fireside Chat
Michael A. Caligiuri - City of Hope National Medical Center, Duarte, CA
Elizabeth M. Jaffee - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Biden Cancer Initiative Colloquium

Watch the webcast.

Greg Simon (Moderator) - Biden Cancer Initiative, Washington, D.C.
Elizabeth M. Jaffee (Opening remarks) - Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

NGS Oncopanels: Regulatory Considerations

Watch the webcast.

Reena Philip (Chair) - FDA, Silver Spring, MD

Biosimilars: Biological Science, Regulatory Science, and Clinical Practice

Watch the webcast.

Sara A. Hurvitz (Chair) - UCLA, Santa Monica, CA

Cancer Genomic Reference Samples - Sequencing Consortium Results and Beyond

Watch the webcast.

Zivana Tezak (Chair) - FDA, Silver Spring, MD

Has Pandora's Box Been Opened? The Site Agnostic Approval of Pembrolizumab

Watch the webcast.

Steven J. Lemery (Chair) - FDA, Silver Spring, MD

Scientific and Regulatory Challenges in Development of CAR-T Therapy for Solid Tumors

Watch the webcast.

Ke Liu (Chair) - FDA, Silver Spring, MD

Real World Evidence in Oncology and its Implications

Watch the webcast.

Amy P. Abernethy (Chair) - Flatiron Health, New York, NY

Precision Therapy: When Is Better: Up Front or at Relapse?

Watch the webcast.

Gideon Blumenthal (Chair) - FDA, Silver Spring, MD

Recently Approved Breakthrough Therapies and New Approval Endpoints

Watch the webcast.

Ashley F. Ward (Chair) - FDA, Silver Spring, MD

FDA Priorities: A Conversation with Deputy Commissioner Anna Abram

Watch the webcast.

Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development

Watch the webcast.

Gregory H. Reaman (Chair) - FDA, Silver Spring, MD

How the AACR is Working for You in Washington: A Town Hall Meeting on Cancer Research Funding and Science Policy Initiatives

Watch the webcast.

George D. Demetri (Chair) - Dana-Farber Cancer Institute, Boston, MA

The Cancer Survivorship Landscape: Potential Focus Areas for the Future

Watch the webcast.

Anna D. Barker (Moderator) - Arizona State University, Scottsdale, AZ

A Town Hall Discussion of AACR's Priorities in Tobacco Policy

Watch the webcast.

Roy S. Herbst (Chair) - Yale Cancer Center, New Haven, CT

Access to Health Care in the Era of Biologically Targeted Therapies

Watch the webcast.

Sara A. Hurvitz (Chair) - UCLA, Santa Monica, CA

Top of page

Register Today: FDA-AACR-SGO Drug Development in Gynecologic Malignancies Workshop    

Date: June 14, 2018. Time: 8 a.m. - 5 p.m.

Register for in-person or webcast participation.

Gynecologic malignancies continue to be a major cause of morbidity and mortality in the United States, resulting in an unmet medical need. The ongoing revolution in oncology that has offered many new therapies to patients with a variety of cancer types has yet to reach these women. With the notable exception of the approvals of bevacizumab, and PARP inhibitors in ovarian cancer, we need to bring increased efforts to bear to spur the development of new treatment.

Goals and Objectives:

  • To provide a forum for open discussion between the FDA, clinicians, laboratory experts, and researchers on the way forward for diagnosis and treatment of gynecologic malignancies;
  • Accelerate the development of immunotherapy in gynecologic malignancies;Facilitate open discussions among all parties in the area of gynecologic malignancies;
  • Obtain input from multiple stakeholders on approaches to novel study designs to leverage rare subtypes in gynecologic malignancies; and
  • Discuss the impact of biomarkers in gynecologic malignancies.

Read the draft agenda.

Workshop Co-chairs:

  • FDA:
    • Sanjeeve Bala, MD, MPH, Clinical Team Leader Gynecologic Malignancies Group, DOP1, OHOP, CDER, FDA
    • Julia A. Beaver, MD, Director, Division of Oncology Products 1 (DOP1), Office of Hematology and Oncology Products (OHOP), Center for Drug Evaluation and Research (CDER), FDA
  • AACR:
    • Deborah K. Armstrong, MD, Director, Breast and Ovarian Surveillance Service; Professor of Oncology, John Hopkins Kimmel Comprehensive Cancer Center
    • Gordon B. Mills, MD, PhD, Co-Director, Zayed Institute for Personalized Cancer Therapy, Department of Systems Biology 1, Division of Cancer Medicine, UT MD Anderson Cancer Center
  • Society of Gynecologic Oncology (SGO):
    • Rebecca Arend, MD, Assistant Professor of Obstetrics & Gynecology, University of Alabama at Birmingham
    • Robert Coleman, MD, FACOG, FACS, Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center
    • Thomas Herzog, MD, Deputy Director & Professor of Obstetrics & Gynecology, University of Cincinnati Cancer Institute

Additionally, select webcast recordings from the FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop held in Bethesda, MD, on February 22-23, 2018, are now available here. Full transcripts and select presentation slides from that workshop are also available. Some presentations have been withheld at the discretion of individual speakers.

Top of page

Register Today: Rally for Medical Research 2018    

Registration is now available for the sixth annual Rally for Medical Research, which will be held Sept. 12-13, 2018, in Washington, D.C. For those who cannot participate in person, the online Rally National Day of Action will take place Sept. 13.

We have reserved a block of rooms at the Rally headquarters hotel at a negotiated rate. Contact to make a reservation at the lower rate.​​

Learn more about 2018 Hill Day Sponsorship Opportunities​​. Stay up-to-date on registration information by visiting the Rally website, Facebook, and Twitter pages.

Top of page